# EA2183 (NCT04248452)

> Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: oligometastatic HER2-negative esophageal and gastric adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04248452
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Oligometastatic Esophageal Adenocarcinoma; Oligometastatic Gastric Adenocarcinoma; Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Interventions: Capecitabine; Fluorouracil; Leucovorin; Leucovorin Calcium; Oxaliplatin; Radiation Therapy
- Enrollment: 314
- Primary outcome: Overall survival

## Indexed commentary on EA2183 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ea2183-nct04248452

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04248452", "email": "<work email>"}; the inbox owner confirms by the emailed link.